SCHEMBL3095422

SCHEMBL3095422

CC(=O)N(Cc1ccccc1)c1ccc(O)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 2/20 0.58
ACHE P22303 1/20 0.53
RAB9A P51151 2/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
PDK1 Q15118 5/20 0.46
LTB4R2 Q9NPC1 2/20 0.46
MAPK14 Q16539 1/20 0.45
STAT3 P40763 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
NPC1 O15118 1/20 0.43
JAK2 O60674 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
PAX8 Q06710 1/20 0.43
PDK2 Q15119 2/20 0.43
PDK4 Q16654 2/20 0.43
PDK3 Q15120 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1260164 0.90 ACHE (0.53) TSPOACHERAB9APDK1NR1H4
SCHEMBL12560893 0.84 TSPO (0.57) TSPORAB9ACRHBPCRHR2PDK1
SCHEMBL12536635 0.82 TSPO (0.55) TSPOACHERAB9ACRHBPCRHR2
SCHEMBL12275098 0.81 ESR1 (0.41) ACHEESR1ESR2
SCHEMBL5694553 0.78 TSPO (0.72) TSPORAB9ACRHBPCRHR2LTB4R2
SCHEMBL28514755 0.77 ACHE (0.46) TSPOACHERAB9APDK1STAT3
SCHEMBL1924545 0.77 LTB4R2 (0.51) TSPORAB9APDK1LTB4R2NPC1
SCHEMBL14176611 0.75 TSPO (0.73) TSPORAB9ALTB4R2NPC1ALDH1A1
SCHEMBL12764035 0.75 TSPO (0.77) TSPORAB9ACRHBPCRHR2LTB4R2
SCHEMBL4822461 0.74 TSPO (0.62) TSPORAB9ALTB4R2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
EP-2001880-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2008-12-17 EP disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
WO-2007103308-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 TSPO 1231/4885ACHE 4495/4885RAB9A 2498/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 TSPO 1231/4885ACHE 4495/4885RAB9A 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.